tm
Seeing Is Believing
tm
Seeing Is Believing
SGEN is currently covered by 17 analysts with an average potential upside of $11.45 (9.85%) from yesterday's end of day stock price of $218.99. Seattle Genetics activity chart has currently 225 price targets and 224 ratings on display.
Analysts average stock forecasts to be materialized ratio is 88.45% with an average time for these price targets to be met of 121.97 days.
Highest price target for SGEN is $200, Lowest price target is $125, average price target is $162.5.
Most recent stock forecast was given by ASTHIKA GOONEWARDENE from TRUIST on 18-Oct-2023. First documented stock forecast 12-Feb-2014.
Seagen is a biotechnology company that specializes in the development and commercialization of innovative cancer treatments. The company’s primary revenue channel is from the sales of its oncology products, including ADCETRIS® (brentuximab vedotin), PADCEV® (enfortumab vedotin-ejfv), and TUKYSA® (tucatinib), among others.
ADCETRIS is an antibody-drug conjugate that targets CD30-expressing lymphomas, including Hodgkin lymphoma and systemic anaplastic large cell lymphoma.
PADCEV is an antibody-drug conjugate that targets Nectin-4-expressing solid tumors, including bladder and urothelial cancers.
TUKYSA is a small molecule kinase inhibitor that targets HER2-expressing cancers, including breast cancer.
Seagen also generates revenue through collaborations and partnerships with other pharmaceutical and biotech companies.
For example, the company has partnerships with Genmab A/S, Bristol Myers Squibb, and Astellas Pharma, among others, for the development and commercialization of new cancer therapies.
Seagen Inc. also generates revenue through its manufacturing capabilities. The company has manufacturing facilities in Bothell, Washington, and Switzerland, which are used to produce its own products, as well as products for its partners.
Seagen’s headquarters is in Bothell, Washington. It was formerly known as Seattle Genetics, Inc. and changed its name to Seagen Inc. in October 2020.
Currently, out of the existing stock ratings of SGEN - 18 which are a Hold (30%), 42 which are a Buy (70%)
Analyst name
Rating
Current price target
Potential distance
Previous price target
Date
Price targets met ratio
Average potential upside
Average Time (Days) For PT To Be Met
Performance score
Hold
229
$13.5 (6.26%)
229
1 months 21 days ago
1/4 (25%)
$-8.07 (-3.37%)
45
Buy
229
$13.5 (6.26%)
170
8 months 15 days ago
2/3 (66.67%)
$31.83 (19.93%)
34
Hold
173
$-45.99 (-21.00%)
173
8 months 24 days ago
17/18 (94.44%)
$11.12 (8.87%)
135
Hold
168
8 months 25 days ago
10/10 (100%)
$17.02 (11.07%)
244
Buy
229
$10.01 (4.57%)
210
8 months 25 days ago
10/11 (90.91%)
$31.88 (20.81%)
206
What is SGEN (Seattle Genetics) average time for price targets to be met?
Which analyst has the current highest performing score on SGEN (Seattle Genetics) with a proven track record?
Which analyst has the most public recommendations on SGEN (Seattle Genetics)?
Which analyst is the currently most bullish on SGEN (Seattle Genetics)?
Which analyst is the currently most reserved on SGEN (Seattle Genetics)?
